Dr. Gregory Bell was appointed Monitor by the FTC in several healthcare transactions to monitor Respondents’ compliance with post-merger divestiture obligations and other related requirements of the agreement. Dr. Bell and the CRA team complied with all monitor obligations, including conducting weekly and bi-weekly calls with the respective parties, and submitting a monthly report to the FTC on activities, issues, and opinions related to the divestiture obligations.
Life Sciences Litigation Insights: April 2022
CRA’s Life Sciences Litigation team provides periodic summaries of notable developments in litigation. In this issue, we share notable cases from 2021 and...